Tocqueville Asset Management’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Tocqueville Asset Management’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-2,000	Closed	-$293K	–	752
2021 Q4	$293K	Hold	2,000	–	–	﹤0.01%	645
2021 Q3	$354K	Hold	2,000	–	–	0.01%	600
2021 Q2	$323K	Hold	2,000	–	–	﹤0.01%	624
2021 Q1	$343K	Hold	2,000	–	–	0.01%	617
2020 Q4	$439K	Hold	2,000	–	–	0.01%	561
2020 Q3	$332K	Hold	2,000	–	–	0.01%	555
2020 Q2	$228K	Buy	+2,000	New	+$194K	﹤0.01%	609
2020 Q1	–	Sell	-2,000	Closed	-$258K	–	742
2019 Q4	$258K	Buy	+2,000	New	+$193K	﹤0.01%	666
2016 Q2	–	Sell	-11,950	Closed	-$256K	–	888
2016 Q1	$256K	Sell	11,950 -10,000	-46%	-$224K	﹤0.01%	762
2015 Q4	$694K	Buy	21,950 +2,000	+10%	+$70.6K	0.01%	608
2015 Q3	$687K	Buy	19,950 +5,750	+40%	+$174K	0.01%	628
2015 Q2	$447K	Buy	+14,200	New	+$418K	0.01%	745

Other funds holding MRTX

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Tocqueville Asset Management's MRTX Position: Q1 2022 in Review

Tocqueville Asset Management sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2022, closing a stake of 2,000 shares — an estimated $293K sold.

Tocqueville Asset Management first reported a position in MRTX in Q2 2015 and held it in 12 quarters. The position peaked at $694K in Q4 2015. 253 funds tracked by Wall St. Rank hold MRTX as of Q1 2022.

Tocqueville Asset Management reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
Tocqueville Asset Management sold 2,000 Mirati Therapeutics, Inc. Common Stock shares in Q1 2022, an estimated $293K.
Tocqueville Asset Management first reported a position in Mirati Therapeutics, Inc. Common Stock in Q2 2015 and held it in 12 quarters.
Tocqueville Asset Management's Mirati Therapeutics, Inc. Common Stock position peaked at $694K in Q4 2015.
253 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2022.

Based on Tocqueville Asset Management's 13F filing for Q1 2022, filed 16 May 2022.